Similar Papers

Paper Title
Journal
Date
Author
KIR Haplotype B Donors but Not KIR-Ligand Mismatch Result in a Reduced Risk of Relapse After Haploidentical Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning and a CD3/CD19 Depleted Graft.
Sebastian Michaelis ... Wolfgang A Bethge
Blood | VOL. 120
Sebastian Michaelis, et. al.Sebastian Michaelis ... Wolfgang A Bethge
16 Nov 2012
Biologically Randomized Comparison of Haploidentical Versus Human Leukocyte Antigen-Matched Related Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation
Michael R Grunwald ... Nilanjan Ghosh
Transplantation and Cellular Therapy | VOL. 30
Michael R Grunwald, et. al.Michael R Grunwald ... Nilanjan Ghosh
26 Sep 2024
The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation.
Stefan O Ciurea ...
Bone Marrow Transplantation | VOL. 53
Stefan O Ciurea, et. al.Stefan O Ciurea ...
15 Jan 2018
Dose Reduced Conditioning and CD3/CD19 Depletion for Haploidentical Allogeneic Hematopoietic Cell Transplantation in Adults: Fast Engraftment and Low Toxicity.
Wolfgang A Bethge ... Lothar Kanz
Blood | VOL. 106
Wolfgang A Bethge, et. al.Wolfgang A Bethge ... Lothar Kanz
16 Nov 2005
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Brentuximab vedotin and nivolumab for cHL.
-
Blood | VOL. 145
--
16 Jan 2025
B-1 B cells lose self-control in SCD.
David R Gibb ... Sean R Stowell
Blood | VOL. 145
David R Gibb, et. al.David R Gibb ... Sean R Stowell
16 Jan 2025
Is it time to screen for multiple myeloma?
Irene M Ghobrial ... Floris Chabrun
Blood | VOL. 145
Irene M Ghobrial, et. al.Irene M Ghobrial ... Floris Chabrun
16 Jan 2025
Daratumumab for maintenance in myeloma
Cyrille Touzeau ... Aurore Perrot
Blood | VOL. 145
Cyrille Touzeau, et. al.Cyrille Touzeau ... Aurore Perrot
16 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.